GynecologyGynecologyГинекология2079-56962079-5831Consilium Medicum28385ArticlesСтатьиResearch ArticleGenetic predictors of outcomes of assisted reproductive technologyПрогнозирование исходов программ вспомогательных репродуктивных технологий с использованием молекулярно-генетических маркеровVladimirovaI VВладимироваИнна Владимировнаi_teterina@oparina4.ruKalininaE AКалининаЕлена Анатольевна

д-р мед. наук, зав. отд-нием вспомогательных технологий в лечении бесплодия

DonnikovA EДонниковАндрей Евгеньевич

канд. мед. наук, ст. науч. сотр. лаб. молекулярно-генетических методов

a_donnikov@oparina4.ruФГБУ Научный центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова Минздрава России, Москва15122014166VOL 16, NO6 (2014)ТОМ 16, №6 (2014)333609042020Copyright ©; 2014, Consilium MedicumCopyright ©; 2014, ООО "Консилиум Медикум"2014Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://gynecology.orscience.ru/2079-5831/article/view/28385

Variability in the subfertile patient population excludes the possibility of a single approach to controlled ovarian stimulation. Genetic screening may allow an individual patient’s response to stimulation during controlled ovarian stimulation to be predicted based on genotype. The objective of the study was to analyze the specific features of folliculogenesis, oogenesis, and embryogenesis in patients in relation to single nucleotide polymorphisms in assisted reproductive technology.

Вариабельность овариального ответа среди пациенток в программах экстракорпорального оплодотворения исключает возможность единого подхода к стимуляции функции яичников. Генетический скрининг может позволить прогнозировать исходы стимуляции суперовуляции, индивидуализировать тем самым терапию бесплодия. Цель исследования - поиск молекулярно-генетических предикторов особенностей фолликулогенеза, оогенеза, эмбриогенеза в программах вспомогательных репродуктивных технологий.

single-nucleotide polymorphismgenetic predictorsinfertilityIVFovarian responseполиморфизм геновмолекулярно-генетические предикторыбесплодиеЭКОовариальный ответZegers-Hochschild F, Adamson G.D, de Mouzon J et al. The International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) Revised Glossary on ART Terminology, 2009. Hum Reprod 2009; 24 (11): 2683-7.Rosenbluth E.M, van Voorhis B.J. Evolving role of assisted reproductive technologies. Clin Obstet Gynecol 2011; 54 (4): 734-45.Lledo B, Ortiz J.A, Llacer J, Bernabeu R. Pharmacogenetics of ovarian response. Pharmacogenomics 2014; 15 (6): 885-93.Boudjenah R, Molina-Gomes D, Torre A et al. Genetic polymorphisms influence the ovarian response to rFSH stimulation in patients undergoing in vitro fertilization programs with ICSI. PloS one 2012; 7 (6): e38700.Sunkara S.K, Rittenberg V, Raine-Fenning N et al. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod 2011; 26 (7): 1768-74.Oehninger S. Ovulation induction in IVF. Minerva Ginecol 2011; 63 (2): 137-56.Mutsatsa S, Currid T.J. Pharmacogenetics: a reality or misplaced optimism? J Psychiatr Ment Health Nurs 2013; 20 (4): 314-20.Fauser B.C, Diedrich K, Devroey P. Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation. Hum Reprod Update. 2008; 14 (1): 1-14.Wang J, Pang G.S, Chong S.S, Lee C.G. SNP web resources and their potential applications in personalized medicine. Current Drug Metab 2012; 13 (7): 978-90.Altmae S, Hovatta O, Stavreus-Evers A, Salumets A. Genetic predictors of controlled ovarian hyperstimulation: where do we stand today? Hum Reprod Update 2011; 17 (6): 813-28.Laan M, Grigorova M, Huhtaniemi I.T. Pharmacogenetics of follicle - stimulating hormone action. Curr Opinion Endocrinol Diabetes Obes 2012; 19 (3): 220-7.Livshyts G, Podlesnaja S, Kravchenko S et al. A distribution of two SNPs in exon 10 of the FSHR gene among the women with a diminished ovarian reserve in Ukraine. J Assist Reprod Genet 2009; 26 (1): 29-34.Lledo B, Guerrero J, Turienzo A et al. Effect of follicle-stimulating hormone receptor N680S polymorphism on the efficacy of follicle - stimulating hormone stimulation on donor ovarian response. Pharmacogenet Genomics 2013; 23 (5): 262-8.Mohiyiddeen L, Newman W.G, Cerra C et al. FSH receptor genotype does not predict metaphase-II oocyte output or fertilization rates in ICSI patients. Reprod Biomed Online 2013; 27 (3): 305-9.Desai S.S, Achrekar S.K, Paranjape S.R et al. Association of allelic combinations of FSHR gene polymorphisms with ovarian response. Reprod Biomed Online 2013; 27 (4): 400-6.Desai S.S, Achrekar S.K, Pathak B.R et al. Follicle - stimulating hormone receptor polymorphism (G-29A) is associated with altered level of receptor expression in Granulosa cells. J Clin Endocrinol Metab 2011; 96 (9): 2805-12.Alviggi C, Clarizia R, Pettersson K et al. Suboptimal response to GnRHa long protocol is associated with a common LH polymorphism. Reprod Biomed Online 2009; 18 (1): 9-14.Bentov Y, Kenigsberg S, Casper R.F. A novel luteinizing hormone/chorionic gonadotropin receptor mutation associated with amenorrhea, low oocyte yield, and recurrent pregnancy loss. Fertil Steril 2012; 97 (5): 1165-8.Haasl R.J, Ahmadi M.R, Meethal S.V et al. A luteinizing hormone receptor intronic variant is significantly associated with decreased risk of Alzheimer's disease in males carrying an apolipoprotein E epsilon4 allele. BMC Med Genet 2008; 9: 37.Altmae S, Haller K, Peters M et al. Allelic estrogen receptor 1 (ESR1) gene variants predict the outcome of ovarian stimulation in in vitro fertilization. Mol Human Reprod 2007; 13 (8): 521-6.Ayvaz O.U, Ekmekci A, Baltaci V et al. Evaluation of in vitro fertilization parameters and estrogen receptor alpha gene polymorphisms for women with unexplained infertility. J Assist Reprod Genetics 2009; 26 (9-10): 503-10.Hanevik H.I, Hilmarsen H.T, Skjelbred C.F et al. Single nucleotide polymorphisms in the anti-Mullerian hormone signalling pathway do not determine high or low response to ovarian stimulation. Reprod Biomed Online 2010; 21 (5): 616-23.Yoshida Y, Yamashita Y, Saito N et al. Analyzing the possible involvement of anti-Mullerian hormone and anti-Mullerian hormone receptor II single nucleotide polymorphism in infertility. J Assist Reprod Genet 2014; 31 (2): 163-8.Dupakuntla M, Mahale S.D. Accessibility of the extracellular loops of follicle stimulating hormone receptor and their role in hormone - receptor interaction. Mol Cell Endocrinol 2010; 315 (1-2): 131-7.Moron F.J, Galan J.J, Ruiz A. Controlled ovarian hyperstimulation pharmacogenetics: a simplified model to genetically dissect estrogen - related diseases. Pharmacogenomics 2007; 8 (7): 775-85.Yao Y, Ma C.H, Tang H.L, Hu Y.F. Influence of follicle - stimulating hormone receptor (FSHR) Ser680Asn polymorphism on ovarian function and in - vitro fertilization outcome: a meta - analysis. Mol Genet Metab 2011; 103 (4): 388-93.Jun J.K, Yoon J.S, Ku S.Y et al. Follicle - stimulating hormone receptor gene polymorphism and ovarian responses to controlled ovarian hyperstimulation for IVF-ET. J Hum Genet 2006; 51 (8): 665-70.Jiang X, Dias J.A, He X. Structural biology of glycoprotein hormones and their receptors: insights to signaling. Mol Cell Endocrinol 2014; 382 (1): 424-51.Berger K, Billerbeck A.E, Costa E.M et al. Frequency of the allelic variant (Trp8Arg/Ile15Thr) of the luteinizing hormone gene in a Brazilian cohort of healthy subjects and in patients with hypogonadotropic hypogonadism. Clinics 2005; 60 (6): 461-4.Ziecik A.J, Kaczmarek M.M, Blitek A et al. Novel biological and possible applicable roles of LH/hCG receptor. Mol Cell Endocrinol 2007; 269 (1-2): 51-60.Perrier d’Hauterive S, Berndt S, Tsampalas M et al. Dialogue between blastocyst hCG and endometrial LH/hCG receptor: which role in implantation? Gynecol Obstet Investig 2007; 64 (3): 156-60.O’Brien T, Kalmin M.M, Harralson A.F et al. Association between the luteinizing hormone/chorionic gonadotropin receptor (LHCGR) rs4073366 polymorphism and ovarian hyperstimulation syndrome during controlled ovarian hyperstimulation. Reprod Biol Endocrinol 2013; 11 (1): 71.O’Brien T.J, Kalmin M.M, Harralson A.F et al. Association between the luteinizing hormone/chorionic gonadotropin receptor (LHCGR) rs4073366 polymorphism and ovarian hyperstimulation syndrome during controlled ovarian hyperstimulation. Reproductive biology and endocrinology 2013; 11 (1): 71.Anagnostou E, Mavrogianni D, Theofanakis C et al. ESR1, ESR2 and FSH receptor gene polymorphisms in combination: a useful genetic tool for the prediction of poor responders. Curr Pharmaceutical Biotech 2012; 13 (3): 426-34.Nelson S.M, Yates R.W, Lyall H et al. Anti-Mullerian hormone - based approach to controlled ovarian stimulation for assisted conception. Hum Reprod 2009; 24 (4): 867-75.Kevenaar M.E, Themmen A.P, Laven J.S et al. Anti-Mullerian hormone and anti-Mullerian hormone type II receptor polymorphisms are associated with follicular phase estradiol levels in normo - ovulatory women. Hum Reprod 2007; 22 (6): 1547-54.Ferraretti A.P, La Marca A, Fauser B.C et al. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod 2011; 26 (7): 1616-24.American Society of Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril 2008; 90 (5. Suppl.): S188-193.Delvigne A. Symposium: Update on prediction and management of OHSS. Epidemiology of OHSS. Reprod Biomed Online 2009; 19 (1): 8-13.The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting. Hum Reprod 2011; 26 (6): 1270-83.